Peptide Receptor–Targeted Radionuclide Therapy Alters Inflammation in Atherosclerotic Plaques

64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients

“…5) is primarily caused by the difference in radiotracer emission energy between 64 Cu and 68 Ga and thus related to the spatial resolution of the examination rather than a physiologic difference in tracer binding. Still, other studies have shown a correlation between DOTATATE labeled with 68 Ga and risk factors (6,8,27). However, more atherosclerotic vessels in these studies may be the cause hereof.…”

“…The somatostatin analogs DOTATOC and DOTATATE bind to somatostatin receptors, with highest affinity for the somatostatin receptor 2. Hence, they might be potential tracers for molecular imaging of atherosclerosis (7,8). A recent prospective study in patients with symptomatic carotid stenosis has indicated that uptake of 64 Cu-DOTATATE is a marker of activated macrophages within the plaque (9).…”

Cardiovascular magnetic resonance imaging and clinical performance of somatostatin receptor positron emission tomography in cardiac sarcoidosis

“…Among these, gallium scintigraphy and 18 F‐FDG PET/CT represent the best‐studied techniques, with the latter offering a higher sensitivity than single photon‐emitting procedures 29. SSTR‐directed PET/CT has been demonstrated to be feasible for imaging atherosclerotic and myocardial inflammatory processes 10, 30. The potential of SSTR‐directed PET/CT in the field of granulomatous diseases has foremost been described for 111 In‐labelled octreotide 31…”

Evaluation of inflamed coronary atherosclerotic plaques by PET: More evidences for a promising area of cardiovascular imaging

“…1 Other possible tracers of inflammation such as somatostatin-analogs have been also studied. A paper by Schatka et al 2 reported that 68Ga-DOTATATE PET/CT can characterize biologic activity of atherosclerotic plaque via SSTR-2 expression and that a targeted therapy with DOTATATE-based SSTR-2 results in a reduction of atherosclerotic plaque activity, thus suggesting a possible therapy strategy. Now, the work by Blomberg et al 3 adds another tessera in the process of optimizing PET/CT protocols in the evaluation of CAD and seems to rehabilitate FDG as an important tracer of atherosclerotic lesions.…”